Diagenode Launches First CRISPR/Cas9 Antibody Validated for Chromatin Immunoprecipitation
Denville, NJ (PRWEB) September 23, 2015 -- Diagenode, Inc., a leading global provider of complete solutions for epigenetics research, recently launched the industry’s first polyclonal antibody targeting CRISPR/Cas9 validated for chromatin immunoprecipitation. The antibody has been raised against the N-terminus of the Cas9 nuclease, extensively validated and optimized for excellent specificity and high yields in chromatin IP. It can also be used effectively in a number of applications including western blotting, immunoprecipitation, and immunofluorescence to determine protein localization.
The CRISPR/Cas system has been most commonly used for gene editing such as in gene silencing or changing specific genes in both bacterial systems and eukaryotic systems. In addition, Cas9 can also be used to mediate upregulation or downregulation of specific endogenous genes or to alter histone modifications or DNA methylation. The new polyclonal antibody will allow researchers to supplement their CRISPR/Cas studies for ChIP and other applications.
“Diagenode has been a trusted supplier of highly sensitive, validated epigenetic antibodies. We are pleased to expand our offering of validated monoclonal CRISPR/Cas9 antibodies with the first polyclonal CRISPR/Cas9 specifically validated for chromatin immunoprecipitation,” stated Didier Allaer, CEO of Diagenode. “The new CRISPR/Cas9 antibody is superior to epitope-tagged antibodies and provides much higher sensitivity.”
More information can be found at https://www.diagenode.com/landingPages/display/CAS9-chip-grade-antibody
About Diagenode, Inc.:
Diagenode is a leading provider of complete solutions for epigenetic research. The company has developed a comprehensive approach to gain new insights into epigenetic studies, offering innovative shearing and automation instruments, reagent kits, and high quality antibodies to streamline DNA methylation, ChIP, and ChIP-seq workflows. The company’s latest innovations include a unique, full automation system, a Reduced Representation Bisulfite Sequencing (RRBS) Kit providing eight times more coverage than standard technologies, ChIP-seq kits for only 10,000 cells, and the industry’s most validated antibodies. For more information about Diagenode, please visit the company’s website at http://www.diagenode.com.
Didier Allaer, Diagenode, Inc., +1 8587747501, [email protected]
Share this article